Abstract
New treatment modalities have been recently introduced in the management of ovarian cancer (OC). Herein, we sought to investigate their implementation in routine clinical practice and examine the real-world management of OC in Greece. EpOCa was a non-interventional, multicenter, retrospective study in patients with advanced epithelial OC. The primary outcome was to estimate the proportions of the different treatment regimens used per line of therapy, while progression-free survival (PFS) and overall survival (OS) were the key secondary endpoints. A total of 154 patients were enrolled in the study, among whom, 40% were tested for BRCA mutations and 30% were found to be positive. Nearly 90% of patients underwent debulking surgery at diagnosis, with few operations being also recorded upon relapse. Platinum-based chemotherapy (CT) was predominantly used in the first line with half of patients also receiving angiogenesis inhibitor (AI), while non-platinum-based CT was preferred in later lines. The median PFS was 18.2 and 8.8 months in the first- and second-line setting, respectively, whereas the median OS was approximately 50 months. Our study adds to the available, but limited, real world data on the management of ovarian cancer providing evidence regarding the applied treatment strategies and outcomes of patients in Greece.
Highlights
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer, representing the seventh most commonly diagnosed cancer among women in the world, with a 5-year survival rate of 44–46%
Eligible patients had been diagnosed with advanced EOC (aEOC) between 25 September 2013 and 1 March 2016 (Figure 1)
The median retrospective look-back period, defined as the time elapsed from aEOC diagnosis to death for deceased
Summary
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer, representing the seventh most commonly diagnosed cancer among women in the world, with a 5-year survival rate of 44–46%. One of the main factors contributing to the high death-to-incidence rate is the advanced stage of the disease at the time of diagnosis [1–3]. In the newly-diagnosed advanced EOC (aEOC) setting, the current standard-of-care treatment involves primary debulking surgery followed by platinum- and taxane-based combination chemotherapy (CT) which, despite high initial response rates, eventually results in disease recurrence in most cases [4–7]. EOC is probably the tumor type with the highest percentage of hereditary cases. Pathogenic germline variants in BRCA1/2 are responsible for the largest part of hereditary ovarian cancer. Beyond BRCA1/2, additional genes are suspected to participate in ovarian carcinogenesis [8,9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
